GlassScriptPhysician profile
Donna L Logan
NPI 1083676084
$1,896.29
in general payments reported to CMS, 2019-2025
30 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $50.74 · 2021: $104 · 2022: $373 · 2023: $407 · 2024: $396 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $364.50 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $230.80 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $196.64 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $129.12 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $116.01 | 2021-2023 | |
| Glaxosmithkline, LLC. | $110.01 | 2022-2025 | Trelegy Ellipta, Shingrix, Penmenvy |
| Lilly USA, LLC | $104.53 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $76.55 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $58.89 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $56.38 | 2020-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Mylan Specialty L.P. | $52.29 | 2019-2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.48 | 2025 | Caplyta |
| Medtronic, INC. | $38.45 | 2025 | Intellis Adaptivestim, Minimed 780g |
| Nevro Corp. | $30.91 | 2024 | Senza |
| Dexcom, INC. | $29.26 | 2025 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $29.16 | 2021-2022 | |
| Gilead Sciences, INC. | $22.17 | 2025 | Yeztugo |
| Sanofi-Aventis U.S. LLC | $20.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.49 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.21 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $16.64 | 2023 | |
| Vivus LLC | $16.64 | 2019 | |
| Cranial Technologies, INC | $16.50 | 2025 | Doc Band |
| Biohaven Pharmaceutical Holding Company LTD. | $16.06 | 2022 | |
| Seqirus USA INC | $15.28 | 2025 | Flucelvax |
| Biohaven Pharmaceuticals, INC. | $15.12 | 2021 | |
| Sanofi Pasteur INC. | $14.95 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.92 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.00 | 2019 | |
| Allergan, INC. | $11.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Logan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.